Article Text

THU0444 Assessment of Global Disease Activity in RA by Patients and Physicians: Cultural Differences across Countries in the Meteor Database
  1. E. Gvozdenovic1,
  2. C. Allaart1,
  3. R. Wolterbeek1,
  4. C. Brenol2,
  5. A. Chopra3,
  6. M. Dougados4,
  7. P. Emery5,
  8. G. Ferraccioli6,
  9. D. Van Der Heijde1,
  10. T. Huizinga1,
  11. J. Kay7,
  12. E. Mola8,
  13. R. Moots9,
  14. J. Da Silva10,
  15. J. Smolen11,
  16. D. Veale12,
  17. R. Landewé13
  1. 1LUMC, Leiden, Netherlands
  2. 2Hospital Clinicas, Porto Alegre, Brazil
  3. 3centre rheumatic diseases, Pune, India
  4. 4Cochin Hospital, Paris, France
  5. 5University of Leeds, Leeds, United Kingdom
  6. 6Catholic University Sacred Heart, Rome, Italy
  7. 7UMass Medical School, Worcester, MA, United States
  8. 8Hospital La Paz, Madrid, Spain
  9. 9Hospital Aintree, Liverpool, United Kingdom
  10. 10University, Coimbra, Portugal
  11. 11Medical University, Vienna, Austria
  12. 12Medicine Beaumont Hospital, Dublin, Ireland
  13. 13AMC, Amsterdam, Netherlands


Background Dissonant perceptions of disease activity between rheumatoid arthritis (RA) patients and their rheumatologists may influence treatment decisions. The discordance between patient's and physician's global disease activity assessment (PtGDA and PhGDA, respectively) may vary by country because of cultural differences.

Objectives To compare the differences between PtGDA and PhGDA among 13 countries in the METEOR database.

Methods The Measurement of efficacy of Treatment in the Era of Rheumatology (METEOR) database, a worldwide online tool for disease monitoring in RA, was used to anonymously select 23,117 visits in 5,709 patients during the period between 2008 and 2012. PtGDA and PhGDA were scored independently on a 100 mm visual analogue scale (VAS) with 0 and 100 as extremes. Linear Mixed Models (LMM) were used to estimate the mean differences between PtGDA and PhGDA score in13 countries (Brazil, Czech Republic, Spain, France, United Kingdom, Ireland, Italy, Latvia, Mexico, Pakistan, Portugal, United States, and the Netherlands), adjusted for DAS. Generalized Estimated Equation (GEE) was used to model differences (>20mm) between PtGDA and PhGDA score as the outcome and countries as determinants, corrected for DAS.

Results Mean difference between PtGDA and PhGDA score differs by country, varying from -2 mm (physician scores higher) in Mexico to 14 mm (patient scores higher) in Brazil (Figure 1), independent of DAS. GEE indicated that “country” was a significant determinant of the difference between PtGDA and PhGDA score, independent of differences in DAS. With the Netherlands as a reference, PtGDA and PhGDA scores differ significantly within the same patient in almost all countries (Brazil, Czech Republic, Great Britain, Ireland, Italy, Latvia, Mexico, Pakistan, Portugal and United States).

Figure 1.

Crude mean difference (mm) between patient (PtGDA) and physician (PhGDA) global disease activity score per country*.

Conclusions We find differences between patients' and physicians' assessment of global disease activity, the magnitude of which varies depending upon the country in which the patient and the physician both reside. Cultural influences must be taken into account when interpreting discordances between the patient's and the physician's assessment of global disease activity in RA. Although the magnitude differs across countries, patients nearly always assess global disease activity to be worse than do their physicians.

Disclosure of Interest : E. Gvozdenovic: None declared, C. Allaart: None declared, R. Wolterbeek: None declared, C. Brenol: None declared, A. Chopra: None declared, M. Dougados: None declared, P. Emery: None declared, G. Ferraccioli: None declared, D. Van Der Heijde: None declared, T. huizinga: None declared, J. Kay: None declared, E. Mola: None declared, R. Moots: None declared, J. Da Silva: None declared, J. Smolen: None declared, D. Veale: None declared, R. Landewé Grant/research support: Pfizer

DOI 10.1136/annrheumdis-2014-eular.4982

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.